Affimed Past Earnings Performance

Past criteria checks 0/6

Affimed's earnings have been declining at an average annual rate of -37.5%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 2.6% per year.

Key information

-37.5%

Earnings growth rate

-19.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate2.6%
Return on equity-183.3%
Net Margin-761.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15
The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Oct 10

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Sep 17
Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Affimed Q2 2022 Earnings Preview

Aug 10

Affimed: Preparing For Key Inflection Points

Jun 29

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Jun 14
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Stock: 3 Points For The Bulls

Apr 09

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Apr 05
Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Dec 14
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed: Preparing For A Bullish 2022

Oct 12

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Aug 19
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed: Current Fall And Future Prospects

Jul 07

We Discuss Why Affimed N.V.'s (NASDAQ:AFMD) CEO May Deserve A Higher Pay Packet

Jun 08
We Discuss Why Affimed N.V.'s (NASDAQ:AFMD) CEO May Deserve A Higher Pay Packet

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20
Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15
Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Affimed N.V. initiates equity offering

Jan 12

Affimed inks €25M debt financing deal with Silicon Valley Bank

Jan 11

Affimed updates on product pipeline and cash balances

Jan 07

Affimed (NASDAQ:AFMD) Has Debt But No Earnings; Should You Worry?

Dec 25
Affimed (NASDAQ:AFMD) Has Debt But No Earnings; Should You Worry?

What Did Affimed's (NASDAQ:AFMD) CEO Take Home Last Year?

Dec 04
What Did Affimed's (NASDAQ:AFMD) CEO Take Home Last Year?

Revenue & Expenses Breakdown
Beta

How Affimed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:AFMD Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2314-1062593
30 Sep 2321-11926110
30 Jun 2334-11129114
31 Mar 2339-10132110
31 Dec 2243-863297
30 Sep 2242-763193
30 Jun 2236-763087
31 Mar 2238-762788
31 Dec 2142-582481
30 Sep 2141-492171
30 Jun 2143-381860
31 Mar 2136-321550
31 Dec 2029-411450
30 Sep 2022-391246
30 Jun 2014-441247
31 Mar 2015-431147
31 Dec 1921-321044
30 Sep 1941-111143
30 Jun 1939-121041
31 Mar 1935-91037
31 Dec 1824-191035
30 Sep 182-35928
30 Jun 182-31824
31 Mar 182-31822
31 Dec 172-30821
30 Sep 173-29822
30 Jun 173-31925
31 Mar 175-32928
31 Dec 166-32930
30 Sep 167-33831
30 Jun 167-30829
31 Mar 167-27826
31 Dec 158-20822
30 Sep 157-19819
30 Jun 157-5615
31 Mar 1561407
31 Dec 144039
30 Sep 1482211
30 Jun 147-16511
31 Mar 146-381118
31 Dec 136-26714

Quality Earnings: AFMD is currently unprofitable.

Growing Profit Margin: AFMD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AFMD is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.

Accelerating Growth: Unable to compare AFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AFMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).


Return on Equity

High ROE: AFMD has a negative Return on Equity (-183.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.